This Week in Cardiology

More from ESC including: Valvular HD guidelines, a new drug class for HTN, myosin inhibition in HCM, vericiguat, and digoxin are the topic discussed by John Mandrola, MD. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I New European Valvular Heart Disease Guidelines 2025 ESC/EACTS Guidelines for the management of valvular heart disease  https://doi.org/10.1093/eurheartj/ehaf194 Debate: Does Asymptomatic Aortic Stenosis Warrant Early Intervention? https://exp.medscape.com/debates/does-asymptomatic-aortic-stenosis-warrant-early-intervention/ Surgical Ablation of Atrial Fibrillation during Mitral-Valve Surgery https://www.nejm.org/doi/full/10.1056/NEJMoa1500528 Surgical ablation of atrial fibrillation: a systematic review and meta-analysis https://doi.org/10.1093/europace/eux336 II  New Drug for Resistant HTN Baxdrostat: A 'Game Changer' for Hypertension? https://www.medscape.com/viewarticle/baxdrostat-game-changer-hypertension-2025a1000mz7 Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension https://www.nejm.org/doi/full/10.1056/NEJMoa2507109 Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension https://www.nejm.org/doi/10.1056/NEJMoa2501440 III HCM News at ESC New Trials Clarify Role of Myosin Inhibitors for Hypertrophic Cardiomyopathy https://www.medscape.com/viewarticle/new-trials-clarify-role-myosin-inhibitors-hypertrophic-2025a1000myv MAPLE HCM https://www.nejm.org/doi/full/10.1056/NEJMoa2504654 SEQUOIA HCM https://www.nejm.org/doi/10.1056/NEJMoa2401424 ODYSSEY HCM https://www.nejm.org/doi/full/10.1056/NEJMoa2505927 IV Vericiguat at ESC New Data Said to Support Vericiguat as Standard Therapy for Heart Failurehttps://www.medscape.com/viewarticle/new-data-said-support-vericiguat-standard-therapy-heart-2025a1000mz9 VICTOR https://doi.org/10.1016/S0140-6736(25)01665-4 VICTORIA https://www.nejm.org/doi/full/10.1056/NEJMoa1915928 An individual participant data analysis of the VICTORIA and VICTOR trials https://doi.org/10.1016/S0140-6736(25)01682-4 V More on Digoxin RATE AF substudy https://doi.org/10.1002/ejhf.70022 Main RATE-AF trial https://jamanetwork.com/journals/jama/fullarticle/2774407 Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis https://doi.org/10.1016/S0140-6736(14)61373-8 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Explore the evolving role of beta-blockers after myocardial infarction and the latest insights from the ESC conference. Tune in for discussions on dual pathway therapy combining aspirin and oral anticoagulants, which might pose significant risks. Learn about the implications of stopping oral anticoagulants post-AF ablation and the notable findings from the DANCAVAS II trial. The conversation emphasizes evidence-based practices and the importance of continued research in cardiology.

Explore the surprising implications of coronary artery calcium scans and their links to LDL cholesterol. Dive into the Digit-HF trial, revealing how Digitoxin can reduce mortality in heart failure. Discover innovative potassium management strategies from the PODCAST trial that may lower arrhythmias in ICD patients. Plus, a critical look at the true benefits of implantable cardioverter-defibrillators. This discussion promises valuable insights for healthcare professionals navigating the latest in cardiac care.

John Mandrola delves into the differences between conduction system pacing and standard pacing, backed by recent trial findings. The discussion includes the implications of adjusting heart failure medications once atrial fibrillation is resolved. Insights from patient outcome data reveal concerning mortality rates in left atrial appendage occlusion procedures, emphasizing the necessity for improved patient selection, particularly among frail individuals. Anticipation builds for upcoming hypertension guidelines and studies at the Madrid ESC conference.

Discover the latest hypertension guidelines emphasizing prompt treatment and the importance of careful management. Learn about the surprising impacts of ultra-processed foods on cardiometabolic health. Explore innovative solutions for refractory angina, including the promising coronary sinus reducer. Plus, delve into the effectiveness of pulsed field ablation for atrial fibrillation, revealing its advantages over traditional methods. A crucial listen for keeping up with advancements in cardiovascular care!

Listener feedback on the Surpass Cardiovascular Outcomes Trial reveals key insights about diabetes medications and heart health. A deep dive into atrial fibrillation ablation techniques showcases the debate between catheter and surgical approaches. An FDA alert warns of air embolism risks associated with Watchman systems, sparking concerns among medical professionals. Lastly, managing anticoagulation in frail elderly patients presents unique challenges, spotlighting recent trials that guide treatment decisions.

Exercise and CV outcomes, aldosterone modulation, AI for ECG reading, GLP-1 comparisons, end-of-life decisions, and another well-meaning policy that caused harm in veterans are discussed by John Mandrola, MD, in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Exercise and CV outcomes II Aldosterone Modulation in Cardio-Kidney Disease Aldosterone and Aldosterone Modulation https://doi.org/10.1016/j.jacc.2025.06.012 Randomized Aldactone Evaluation Study https://www.nejm.org/doi/full/10.1056/NEJM199909023411001 III AI vs MD ECG-Reading for Cath Lab Activation Accuracy of Cath Lab Activation Decisions https://doi.org/10.1016/j.ajem.2025.07.061 IV Tirzepatide vs Dulaglutide - SURPASS CVOT Study Eli Lilly Press Release https://investor.lilly.com/news-releases/news-release-details/lillys-mounjaro-tirzepatide-gipglp-1-dual-agonist-demonstrated REWIND Study 10.1016/S0140-6736(19)31149-3 External Link V End-of-Life Decisions Doctors’ Own End-of-Life Choices Defy Common Medical Practice https://www.medscape.com/viewarticle/doctors-own-end-life-choices-defy-common-medical-practice-2025a1000k01 Physicians’ Preferences for Their Own End of Life https://jme.bmj.com/content/early/2025/06/05/jme-2024-110192 How US Doctors Die: A Cohort Study https://agsjournals.onlinelibrary.wiley.com/doi/full/10.1111/jgs.14112 VI Well-Meaning Policies That Make Sense   The Mission Act and Cardiovascular Procedures https://jamanetwork.com/journals/jama/fullarticle/2837067 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Discover the surprising cardiac risks of endurance athletes revealed in the VENTOUX study, highlighting potential heart issues tied to intense training. Uncover the truth behind the 10,000-step myth, as new research suggests even 7,000 steps can boost health. Delve into the debate over rate versus rhythm control for atrial fibrillation and learn about the impact of GLP-1 drugs in observational studies, linking them to neurodegeneration and stroke. It's a deep dive into the complexities of heart health!

Discover the latest on finerenone's FDA approval for heart failure and the complexities of choosing between TAVI and surgical AVR for aortic stenosis. Dive into the risks of catheter ablation, including brain lesions and visual migraines, as revealed by the TRAVERSE trial. The discussion also evaluates the impacts of atrial fibrillation treatments on brain health. With critiques of recent studies and a hopeful look at healthcare policy reforms, there's a wealth of engaging insights for healthcare professionals.

Dive into the world of cardiology controversies, including the heated debate over ticagrelor's efficacy and safety in trials. Discover insights on the longevity of ICD batteries and what it means for patient care. The PRAGUE-25 trial is highlighted as a pivotal study this year, stimulating discussions on the future of electrophysiology as a profession. The episode also features personal anecdotes blending professional insights with lighthearted moments from recent celebrations.